‘Not only was the clearance rate better with brodalumab, however the right time it took until clearance was attained was less when compared to ustekinumab [Stelara],’ said Burris. Burris cautioned, however, that ‘the long-term safety of the new medication will end up being determined upon further research and can hopefully be as safe and sound since it is efficacious.’ Side effects from brodalumab included slight to moderate yeast infections, Lebwohl said. These attacks were easy to treat and no one stopped the drug due to contamination, he said. However, two sufferers committed suicide. ‘I have no idea of any system why the drug would result in despair or suicide,’ he stated.5, 2015/PRNewswire/ –Allergan plc andKYTHERA Biopharmaceuticals, Inc. today announced they have amended and restated their merger agreement with respect toAllergan'spending acquisition of KYTHERA to supply for all-cash consideration to KYTHERA's stockholders. The agreement amends and restates the original merger agreement entered into by the celebrations onJune 17, 2015, as amended onJuly 1, 2015. Pursuant to the amended and restated agreement,Allerganand KYTHERA have agreed to revise the framework of their previously announced deal to provide that the$75per share merger thought to end up being paid to KYTHERA stockholders will end up being paid entirely in cash, instead of 80 percent cash and 20 percent stock as provided for under the original contract.